Ashok Kumar Pandurangan

Dr. Ashok Kumar Pandurangan

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
Ashok Kumar PanduranganAshok Kumar Pandurangan
Ashok Kumar Pandurangan
Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways Colon cancer;PI3K/Akt;mTOR;Wnt/${\beta}$-catenin;chemoprevention;flavonoids; Colorectal cancer (CRC) is one of the most common cancers in many parts of the world. Its development is a multi-step process involving three distinct stages, initiation that alters the molecular message of a normal cell, followed by promotion and progression that ultimately generates a phenotypically altered transformed malignant cell. Reports have suggested an association of the phosphoinositide-3-kinase (PI3K)/Akt pathway with colon tumorigenesis. Activation of Akt signaling and impaired expression of phosphatase and tensin homolog (PTEN) (a negative regulator of Akt) has been reported in 60-70% of human colon cancers and inhibitors of PI3K/Akt signaling have been suggested as potential therapeutic agents. Around 80% of human colon tumors possess mutations in the APC gene and half of the remainder feature ${\beta}$-catenin gene mutations which affect downstream signaling of the PI3K/Akt pathway. In recent years, there has been a great focus in targeting these signaling pathways, with natural and synthetic drugs reducing the tumor burden in different experiment models. In this review we survey the role of PI3K/Akt/mTOR and Wnt signaling in CRC.

1 March 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
FBFarahnaz Barahuie
Farahnaz Barahuie
DDDena Dorniani
Dena Dorniani
SBSaifullah Bullo
Saifullah Bullo
SGSivapragasam Gothai
Sivapragasam Gothai
MHMohd Zobir Bin Hussien
Mohd Zobir Bin Hussien
NORHAIZAN MOHD ESANORHAIZAN MOHD ESA
NORHAIZAN MOHD ESA
Sustained release of anticancer agent phytic acid from its chitosan-coated magnetic nanoparticles for drug-delivery system Farahnaz Barahuie,1,2 Dena Dorniani,1,3,* Bullo Saifullah,1,* Sivapragasam Gothai,4 Mohd Zobir Hussein,1 Ashok Kumar Pandurangan,5 Palanisamy Arulselvan,4 Mohd Esa Norhaizan6 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 2Zabol University of Medical Sciences, Zabol, Iran; 3Department of Chemistry, University of Sheffield, Sheffield, UK; 4Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 5Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 6Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia *These authors contributed equally to this work Chitosan (CS) iron oxide magnetic nanoparticles (MNPs) were coated with phytic acid (PTA) to form phytic acid-chitosan-iron oxide nanocomposite (PTA-CS-MNP). The obtained nanocomposite and nanocarrier were characterized by powder X-ray diffraction, Fourier transform infrared spectroscopy, vibrating sample magnetometry, transmission electron microscopy, and thermogravimetric and differential thermogravimetric analyses. Fourier transform infrared spectra and thermal analysis of MNPs and PTA-CS-MNP nanocomposite confirmed the binding of CS on the surface of MNPs and the loading of PTA in the PTA-CS-MNP nanocomposite. The coating process enhanced the thermal stability of the anticancer nanocomposite obtained. X-ray diffraction results showed that the MNPs and PTA-CS-MNP nanocomposite are pure magnetite. Drug loading was estimated using ultraviolet-visible spectroscopy and showing a 12.9% in the designed nanocomposite. Magnetization curves demonstrated that the synthesized MNPs and nanocomposite were superparamagnetic with saturation magnetizations of 53.25 emu/g and 42.15 emu/g, respectively. The release study showed that around 86% and 93% of PTA from PTA-CS-MNP nanocomposite could be released within 127 and 56 hours by a phosphate buffer solution at pH 7.4 and 4.8, respectively, in a sustained manner and governed by pseudo-second order kinetic model. The cytotoxicity of the compounds on HT-29 colon cancer cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The HT-29 cell line was more sensitive against PTA-CS-MNP nanocomposite than PTA alone. No cytotoxic effect was observed on normal cells (3T3 fibroblast cells). This result indicates that PTA-CS-MNP nanocomposite can inhibit the proliferation of colon cancer cells without causing any harm to normal cell. Keywords: nanocomposite, drug delivery, chitosan, phytic acid, HT-29 cell line, controlled release

1 January 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Ashok Kumar PanduranganAshok Kumar Pandurangan
Ashok Kumar Pandurangan
SISalmiah Ismail
Salmiah Ismail
ZSZeinab Saadatdoust
Zeinab Saadatdoust
NORHAIZAN MOHD ESANORHAIZAN MOHD ESA
NORHAIZAN MOHD ESA
The objective of this study is to evaluate the effect of allicin (10 mg/kg body weight, orally) in an experimental murine model of UC by administering 2.5% dextran sodium sulfate (DSS) in drinking water to BALB/c mice. DSS-induced mice presented reduced body weight, which was improved by allicin administration. We noted increases in CD68 expression, myeloperoxidase (MPO) activities, and Malonaldehyde (MDA) and mRNA levels of proinflammatory cytokines, such astumor necrosis factor- (TNF-)α, interleukin- (IL-) 1β, IL-6, andIL-17, and decrease in the activities of enzymic antioxidants such as superoxide dismutase (SOD), Catalase (CAT), Glutathione reductase (GR), and Glutathione peroxidase (GPx) in DSS-induced mice. However, allicin treatment significantly decreased CD68, MPO, MDA, and proinflammatory cytokines and increased the enzymic antioxidants significantly (P<0.05). In addition, allicin was capable of reducing the activation and nuclear accumulation of signal transducer and activator of transcription 3 (STAT3), thereby preventing degradation of the inhibitory protein IκB and inducing inhibition of the nuclear translocation of nuclear factor (NF)-κB-p65 in the colonic mucosa. These findings suggest that allicin exerts clinically useful anti-inflammatory effects mediated through the suppression of the NF-κB and IL-6/p-STAT3Y705pathways.

11 May 2012 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
AKAshok Kumar
Ashok Kumar
Ashok Kumar PanduranganAshok Kumar Pandurangan
Ashok Kumar Pandurangan
FLFang Lu
Fang Lu
HFHenrik Fyrst
Henrik Fyrst
MZMeng Zhang
Meng Zhang
JSJulie Saba
Julie Saba
Sphingadienes (SDs) derived from soy and other natural sphingolipids are cytotoxic to colon cancer cells via an Akt-dependent mechanism and reduce adenoma formation in Apc Min/+ mice. Wnt signaling is fundamental to colon carcinogenesis and is the basis for spontaneous tumorigenesis in Apc Min/+ mice and patients with familial adenomatous polyposis. In the present study, we investigated the impact of SDs on Wnt signaling. Oral SD administration reduced levels of active β-catenin and Wnt targets c-Myc and cyclin D1 in Apc Min/+ mouse intestinal tissues. Colon cancer cells treated with SDs exhibited reduced Wnt transcriptional activity, as well as reduced nuclear β-catenin localization and subsequent reduction in active-β-catenin levels. Further, we observed a decrease in phosphorylated (inactive) GSK3β in SD-treated mice and colon cancer cells. Expression of constitutively active myristoylated-Akt or inactivation of GSK3β using LiCl attenuated SD-mediated inhibition of Wnt transcriptional activity and active-β-catenin levels. SDs exhibited additive effects with inhibitors of the phosphatidylinositol-3-kinase/Akt/mTOR pathway to induce cytotoxicity. Further, a combination regime of SDs and low-dose rapamycin decreased visible polyps in Apc Min/+ mice and reduced the levels of Wnt target gene expression and mTOR target activation. SD-mediated inhibition of Akt and Wnt pathways and cytotoxicity in colon cancer cells was dependent upon the activity of protein phosphatase 2A, as shown by reversal of these effects by pretreatment with okadaic acid or calyculin A. Our cumulative findings indicate that SDs inhibit Wnt signaling through a protein phosphatase 2A/Akt/GSK3β-dependent mechanism that may contribute to their chemopreventive effects in intestinal tumorigenesis.

1 December 2015 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
ZSZeinab Saadatdoust
Zeinab Saadatdoust
Ashok Kumar PanduranganAshok Kumar Pandurangan
Ashok Kumar Pandurangan
SSSuresh Kumar Ananda Sadagopan
Suresh Kumar Ananda Sadagopan
NORHAIZAN MOHD ESANORHAIZAN MOHD ESA
NORHAIZAN MOHD ESA
AIAmin Ismail
Amin Ismail
MMMohd. Rais Mustafa
Mohd. Rais Mustafa

30 April 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
Ashok Kumar PanduranganAshok Kumar Pandurangan
Ashok Kumar Pandurangan
PDPrakash Dharmalingam
Prakash Dharmalingam
SSSuresh Kumar Ananda Sadagopan
Suresh Kumar Ananda Sadagopan
SGSudhandiran Ganapasam
Sudhandiran Ganapasam
Luteolin (LUT), a bioflavonoid has been used as a chemopreventive agent world-wide against chemically induced cancer. Hence we designed an experiment to assess chemopreventive action of LUT on lipid peroxidation (LPO) and glycoconjugates in azoxymethane (AOM)-induced colon carcinogenesis. Colon cancer was induced by 15 mg/body kg. body weight of AOM and administration of LUT (at the dose of 1.2 mg/kg. body weight) was till end of the study. Analysis of lipid peroxidative end products such as protein carbonyl (PC), malonadehyde (MDA) and conjucated dienes (CD) demonstrated significant increase in in AOM-induced animals with reduction by LUT (p<0.05) . Increased levels of glycoconjugates such as hexose, hexosamine, sialic acid, fucose and mucoprotein were analyzed in serum and colon tissues examined histopathologically by periodic acid Schiff's (PAS) staining were also reversed by LUT l(p<0.05) . The secondary marker of colon cancer mucin depleted foci (MDF) was assessed in control and experimental group of animals. A characteristic increase of MDF was observed in AOM- induced colon cancer animals. Treatment with LUT decreased the incidence of MDF. These results suggest that LUT alters the expression of glycoconjugates and suppress colon cancer. Hence, we speculate that LUT can be used as a chemopreventive agent to treat colon cancer.